Position: Exec. Director Sales, Germany (m/f/divers)
Reports to: VP & GM, Germany
This position will be responsible for leading the German sales force through a transformation with the objective to drive sales excellence and performance.
The position is very important inside the German organization. However, it also has a lot of global exposure. Moreover, the candidate should be a natural successor to the VP & GM of Germany.
You will ensure leadership development of field managers and will be accountable for achieving revenue goals across all products/indications.
You will find and implement solutions to sales force challenges around patient identification, treatment initiation and retention. The position will set up processes and metrics to monitor success and will apply learnings and drive synergies across products/indications. The position will ensure strong cross functional collaboration especially with marketing and market access teams to maximize and materialize business opportunities.
The position is also responsible for participating in the country strategic & sales planning process in collaboration with the corresponding key stakeholders.
- Lead national Sales Force teams
- Achieve commercial goals including patient identification, patients on therapy targets, and revenue goals
- Collaborate with regional marketing, market access, medical and other functions on strategies and execution to achieve business goals
- Support implementation of in-country strategic and tactical sales plan
- Optimize key sales supporting processes and tools (segmentation, targeting, key account management, new selling model, training etc) in collaboration with business operations
- Drive alignment of sales initiatives within multi-channel communication
- Monitor success of national sales teams, drive business analytics in alignment with commercial analysts, and implement according strategies to address opportunities and challenges
- Manage and regularly report business outcomes to senior management (local & regional)
- Manage sales related budget
- Support the development and implementation of sales incentive plans
- Ensure all sales activities and tactics are conducted in line with the highest ethical and compliance standards
- Minimum of 10 years of Sales experience in the biopharma industry, desired in orphan drugs or highly specialized markets
- Experienced in leading sales teams
- Proven leadership capabilities
- Demonstrated launch experience in a competitive environment
- Key account negotiation skills and familiarity with sales models and training formats
- Excellent interpersonal and leadership skills
- Excellent communication and presentation skills
- Desired experience working in a multicultural or international matrix environment
- Readiness for intensive travel
- Demonstrated knowhow of managing budgets
- Potentially previously BU head or Country Sales Director
- Desired: Rare disease experience and/or experience in Hematology, Nephrology, Metabolic or Neurology
- Desired: previous marketing experience
- Minimum Bachelor degree in business and/or scientific field is required
- Master degree in business administration preferred
- Fluent in English, written and spoken; additional languages are a plus
- Advanced user skills in standard office software applications
Some opportunities happen only once in a lifetime – like a job where you have the extraordinary opportunity to change lives. At Alexion, such opportunities arise through our unwavering mission to serve patients and families affected by rare diseases. These patients are our guiding star, and we act with integrity, urgency, and discipline because we know their lives are at stake.
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies. As the global leader in complement biology and inhibition for more than 20 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) as well as the first and only approved complement inhibitor to treat atypical hemolytic uremic syndrome (aHUS), anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). In addition, the company is developing several mid-to-late-stage therapies, including a second complement inhibitor, a copper-binding agent for Wilson disease and an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases as well as several early-stage therapies, including one for light chain (AL) amyloidosis and a second anti-FcRn therapy. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders. Alexion has been named to the Forbes' list of the World's Most Innovative Companies seven years in a row and is headquartered in Boston, Massachusetts' Innovation District. The company also has offices around the globe and serves patients in more than 50 countries. Further information about Alexion can be found at: www.alexion.com.